{
    "clinical_study": {
        "@rank": "36669", 
        "arm_group": [
            {
                "arm_group_label": "Vilazodone", 
                "arm_group_type": "Experimental", 
                "description": "Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Vilazodone is effective in the treatment\n      of symptoms of Social Anxiety Disorder among adults."
        }, 
        "brief_title": "Study of Vilazodone to Treat Social Anxiety Disorder", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Social Anxiety Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Anxiety Disorders", 
                "Phobic Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "The proposed study is a 12 week double-blind, placebo-controlled trial in which daily doses\n      of vilazodone 20 to 40 mg/day or matching placebo will be administered on a 1:1 ratio.  The\n      study will include 30 outpatients age 18-75 with SAD, generalized subtype who return for at\n      least one post randomization visit where efficacy evaluations are conducted."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Social Anxiety Disorder, generalized subtype\n\n          -  LSAS total score of 70 at visits 1 and 2\n\n        Exclusion Criteria:\n\n          -  Lifetime history of Bipolar disorder or Schizophrenia\n\n          -  Current suicidal risk\n\n          -  Current unstable medical condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712321", 
            "org_study_id": "VII-IT-07"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vilazodone", 
                "description": "Vilazodone 20mg or 40mg taken once daily by mouth", 
                "intervention_name": "Vilazodone", 
                "intervention_type": "Drug", 
                "other_name": "Viibryd"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Matching placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Social Anxiety Disorder", 
            "Social Anxiety", 
            "Social Phobia", 
            "SAD"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10128"
                }, 
                "name": "The Medical Research Network, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study", 
        "overall_official": {
            "affiliation": "The Medical Research Network, LLC", 
            "last_name": "Michael R. Liebowitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All subjects randomized to drug or placebo and returning for at least one subsequent visit will be included in the primary efficacy analyses.", 
            "measure": "Change in Liebowitz Social Anxiety Scale (LSAS) - total score", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline to Final Study Visit: minimum 1 week - maximum 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712321"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Responder rate as defined by a CGI Improvement score of 1 (Very Much Improved) or 2 (Much Improved) at study endpoint.\nRandomized subjects taking minimum target dose (20mg or matching placebo daily) for at least six consecutive weeks will be considered a minimum adequate trial for the purposes of secondary analyses.", 
                "measure": "Responder rate, as defined by Clinical Global Impression of Improvement score of 1 or 2", 
                "safety_issue": "No", 
                "time_frame": "Study Endpoint: minimum 6 weeks - maximum 12 weeks"
            }, 
            {
                "description": "Randomized subjects taking minimum target dose (20mg or matching placebo daily) for at least six consecutive weeks will be considered a minimum adequate trial for the purposes of secondary analyses.", 
                "measure": "Change in the Clinical Global Impression of Severity of Illness score", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Study Endpoint: minimum 6 weeks - maximum 12 weeks"
            }, 
            {
                "description": "Randomized subjects taking minimum target dose (20mg or matching placebo daily) for at least six consecutive weeks will be considered a minimum adequate trial for the purposes of secondary analyses.", 
                "measure": "Change on the LSAS anxiety and avoidance subscales", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Study Endpoint: minimum 6 weeks - maximum 12 weeks"
            }, 
            {
                "description": "Randomized subjects taking minimum target dose (20mg or matching placebo daily) for at least six consecutive weeks will be considered a minimum adequate trial for the purposes of secondary analyses.", 
                "measure": "Change in Hamilton Depression scale total", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Study Endpoint: minimum 6 weeks - maximum 12 weeks"
            }, 
            {
                "description": "Randomized subjects taking minimum target dose (20mg or matching placebo daily) for at least six consecutive weeks will be considered a minimum adequate trial for the purposes of secondary analyses.", 
                "measure": "Change in Hamilton Anxiety scale total", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Study Endpoint: minimum 6 weeks - maximum 12 weeks"
            }, 
            {
                "description": "Subject-assessed responder rate, as defined by a Patient Global Impression of Change score of 1 (Very Much Improved) or 2 (Much Improved) at study endpoint.\nRandomized subjects taking minimum target dose (20mg or matching placebo daily) for at least six consecutive weeks will be considered a minimum adequate trial for the purposes of secondary analyses.", 
                "measure": "Subject-assessed responder rate", 
                "safety_issue": "No", 
                "time_frame": "Study Endpoint: minimum 6 weeks - maximum 12 weeks"
            }
        ], 
        "source": "The Medical Research Network", 
        "sponsors": {
            "collaborator": {
                "agency": "Forest Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "The Medical Research Network", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}